1. Home
  2. EDD vs IVA Comparison

EDD vs IVA Comparison

Compare EDD & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDD
  • IVA
  • Stock Information
  • Founded
  • EDD 2007
  • IVA 2011
  • Country
  • EDD United States
  • IVA France
  • Employees
  • EDD N/A
  • IVA N/A
  • Industry
  • EDD Finance Companies
  • IVA Biotechnology: Pharmaceutical Preparations
  • Sector
  • EDD Finance
  • IVA Health Care
  • Exchange
  • EDD Nasdaq
  • IVA Nasdaq
  • Market Cap
  • EDD 329.4M
  • IVA 359.6M
  • IPO Year
  • EDD N/A
  • IVA 2020
  • Fundamental
  • Price
  • EDD $5.37
  • IVA $5.57
  • Analyst Decision
  • EDD
  • IVA Strong Buy
  • Analyst Count
  • EDD 0
  • IVA 6
  • Target Price
  • EDD N/A
  • IVA $15.33
  • AVG Volume (30 Days)
  • EDD 254.3K
  • IVA 71.1K
  • Earning Date
  • EDD 01-01-0001
  • IVA 09-26-2025
  • Dividend Yield
  • EDD 7.52%
  • IVA N/A
  • EPS Growth
  • EDD N/A
  • IVA N/A
  • EPS
  • EDD N/A
  • IVA N/A
  • Revenue
  • EDD N/A
  • IVA $14,591,573.00
  • Revenue This Year
  • EDD N/A
  • IVA $80.35
  • Revenue Next Year
  • EDD N/A
  • IVA N/A
  • P/E Ratio
  • EDD N/A
  • IVA N/A
  • Revenue Growth
  • EDD N/A
  • IVA N/A
  • 52 Week Low
  • EDD $4.22
  • IVA $1.53
  • 52 Week High
  • EDD $4.95
  • IVA $6.50
  • Technical
  • Relative Strength Index (RSI)
  • EDD 60.31
  • IVA 62.61
  • Support Level
  • EDD $5.21
  • IVA $5.21
  • Resistance Level
  • EDD $5.32
  • IVA $6.10
  • Average True Range (ATR)
  • EDD 0.06
  • IVA 0.41
  • MACD
  • EDD -0.00
  • IVA 0.07
  • Stochastic Oscillator
  • EDD 72.73
  • IVA 61.04

About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.

Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Share on Social Networks: